144 related articles for article (PubMed ID: 15128791)
1. The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.
den Boer AT; van Mierlo GJ; Fransen MF; Melief CJ; Offringa R; Toes RE
J Immunol; 2004 May; 172(10):6074-9. PubMed ID: 15128791
[TBL] [Abstract][Full Text] [Related]
2. Antigen presentation by an immature myeloid dendritic cell line does not cause CTL deletion in vivo, but generates CD8+ central memory-like T cells that can be rescued for full effector function.
Dumortier H; van Mierlo GJ; Egan D; van Ewijk W; Toes RE; Offringa R; Melief CJ
J Immunol; 2005 Jul; 175(2):855-63. PubMed ID: 16002683
[TBL] [Abstract][Full Text] [Related]
3. Enhanced tumor outgrowth after peptide vaccination. Functional deletion of tumor-specific CTL induced by peptide vaccination can lead to the inability to reject tumors.
Toes RE; Blom RJ; Offringa R; Kast WM; Melief CJ
J Immunol; 1996 May; 156(10):3911-8. PubMed ID: 8621930
[TBL] [Abstract][Full Text] [Related]
4. Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication.
van Mierlo GJ; Boonman ZF; Dumortier HM; den Boer AT; Fransen MF; Nouta J; van der Voort EI; Offringa R; Toes RE; Melief CJ
J Immunol; 2004 Dec; 173(11):6753-9. PubMed ID: 15557168
[TBL] [Abstract][Full Text] [Related]
5. Longevity of antigen presentation and activation status of APC are decisive factors in the balance between CTL immunity versus tolerance.
den Boer AT; Diehl L; van Mierlo GJ; van der Voort EI; Fransen MF; Krimpenfort P; Melief CJ; Offringa R; Toes RE
J Immunol; 2001 Sep; 167(5):2522-8. PubMed ID: 11509591
[TBL] [Abstract][Full Text] [Related]
6. In vivo cross-presentation of a soluble protein antigen: kinetics, distribution, and generation of effector CTL recognizing dominant and subdominant epitopes.
Nelson D; Bundell C; Robinson B
J Immunol; 2000 Dec; 165(11):6123-32. PubMed ID: 11086045
[TBL] [Abstract][Full Text] [Related]
7. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
[TBL] [Abstract][Full Text] [Related]
8. DNA fusion vaccines induce targeted epitope-specific CTLs against minor histocompatibility antigens from a normal or tolerized repertoire.
Rice J; Buchan S; Dewchand H; Simpson E; Stevenson FK
J Immunol; 2004 Oct; 173(7):4492-9. PubMed ID: 15383580
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic differences between a T cell-tolerizing and a T cell-activating peptide.
Weijzen S; Meredith SC; Velders MP; Elmishad AG; Schreiber H; Kast WM
J Immunol; 2001 Jun; 166(12):7151-7. PubMed ID: 11390461
[TBL] [Abstract][Full Text] [Related]
10. Expression of a tolerizing tumor antigen in peripheral tissue does not preclude recovery of high-affinity CD8+ T cells or CTL immunotherapy of tumors expressing the antigen.
Ohlén C; Kalos M; Hong DJ; Shur AC; Greenberg PD
J Immunol; 2001 Feb; 166(4):2863-70. PubMed ID: 11160355
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an acidic polymerase epitope of influenza virus elicits a potent antiviral T cell response but delayed clearance of an influenza virus challenge.
Crowe SR; Miller SC; Shenyo RM; Woodland DL
J Immunol; 2005 Jan; 174(2):696-701. PubMed ID: 15634888
[TBL] [Abstract][Full Text] [Related]
12. Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope.
Otahal P; Hutchinson SC; Mylin LM; Tevethia MJ; Tevethia SS; Schell TD
J Immunol; 2005 Jul; 175(2):700-12. PubMed ID: 16002665
[TBL] [Abstract][Full Text] [Related]
13. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
14. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
Rubinstein MP; Kadima AN; Salem ML; Nguyen CL; Gillanders WE; Cole DJ
J Immunol; 2002 Nov; 169(9):4928-35. PubMed ID: 12391205
[TBL] [Abstract][Full Text] [Related]
15. Differentiation of naive CTL to effector and memory CTL: correlation of effector function with phenotype and cell division.
Oehen S; Brduscha-Riem K
J Immunol; 1998 Nov; 161(10):5338-46. PubMed ID: 9820507
[TBL] [Abstract][Full Text] [Related]
16. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses.
Lu J; Higashimoto Y; Appella E; Celis E
J Immunol; 2004 Apr; 172(7):4575-82. PubMed ID: 15034075
[TBL] [Abstract][Full Text] [Related]
17. Stimulation by soluble CD70 promotes strong primary and secondary CD8+ cytotoxic T cell responses in vivo.
Rowley TF; Al-Shamkhani A
J Immunol; 2004 May; 172(10):6039-46. PubMed ID: 15128787
[TBL] [Abstract][Full Text] [Related]
18. CD8+ CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity.
Bijker MS; van den Eeden SJ; Franken KL; Melief CJ; Offringa R; van der Burg SH
J Immunol; 2007 Oct; 179(8):5033-40. PubMed ID: 17911588
[TBL] [Abstract][Full Text] [Related]
19. CD4-directed peptide vaccination augments an antitumor response, but efficacy is limited by the number of CD8+ T cell precursors.
Hanson HL; Kang SS; Norian LA; Matsui K; O'Mara LA; Allen PM
J Immunol; 2004 Apr; 172(7):4215-24. PubMed ID: 15034034
[TBL] [Abstract][Full Text] [Related]
20. Injection of soluble antigen into the anterior chamber of the eye induces expansion and functional unresponsiveness of antigen-specific CD8+ T cells.
McKenna KC; Xu Y; Kapp JA
J Immunol; 2002 Nov; 169(10):5630-7. PubMed ID: 12421942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
